Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Serum Institute of India Pvt. Ltd (SIIPL), in collaboration with the University of Oxford, is developing a novel solution for Men-B disease, advancing global accessibility to life-saving vaccines.

Prof Christoph Tang and Dr. Hayley S. Lavender in the lab where the Men B vaccine has been developed at the Dunn School of Pathology, University of Oxford

In a significant stride towards addressing the challenge of Men-B disease, Serum Institute of India Pvt. Ltd (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation.

This partnership will deliver lifesaving protection against Men-B through the production of a chimeric protein-based vaccine.

The agreement underscores the shared institutional commitment to combat disease caused by Neisseria meningitidis and represents a proactive response to overcome the limitations of currently available Men-B vaccines in terms of efficacy, safety, and coverage.

Read more on the Sir William Dunn School of Pathology website

The full story is also on the Oxford University Innovation website